Cashu Logo
HomeWatchlistNewsSignalsPicks
DJI
-0.63%
SPX
-0.33%
IXIC
-0.22%
FTSE
-0.38%
N225
-0.19%
AXJO
-0.11%
Cashu Logo
Log In
HomeWatchlistNewsSignalsPicks

CYCC beat EPS expectations by 68.20%

Nov 22, 2024, 11:33 AM
0.00%
What does CYCC do
Cyclacel Pharmaceuticals, based in Berkeley Heights, New Jersey, develops cancer medicines focusing on cell cycle and transcriptional regulation. Its key programs include fadraciclib and plogosertib, targeting solid tumors and hematological malignancies.
Cyclacel Pharmaceuticals (CYCC) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Cyclacel Pharmaceuticals's actual EPS was -$2.88, beating the estimate of -$9.06 per share, resulting in a 68.20% surprise.
📡️ Health Care
Earnings Surprise

More Signals

Feature in Progress
This section is under development. Check back soon for updates!
Cashu Logo Alt
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.

Company

  • About Us
  • Careers
  • Blog
  • News

Help & Support

  • Help Center
  • Contact Us
  • Pro Support

Legal

  • Privacy Policy
  • Terms of Use
InstagramYouTube

© 2024 Cashu PTY LTD.